Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study

Radiotherapy and Oncology

Volumn 88, Issue 3, 2008, Pages 359-367

  Baumann, Pia ^a   Nyman, Jan ^d   Hoyer, Morten ^e   Gagliardi, Giovanna ^a   Lax, Ingmar ^a   Wennberg, Berit ^a   Drugge, Ninni ^d   Ekberg, Lars ^b   Friesland, Signe ^a   Johansson, Karl Axel ^d   Lund, Jo Åsmund ^f   Morhed, Elisabeth ^c   Nilsson, Kristina ^c   Levin, Nina ^f   Paludan, Merete ^e   Sederholm, Christer ^g   Traberg, Anders ^e   Wittgren, Lena ^b   Lewensohn, Rolf ^a  

^a Divisions of Oncology   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

COPD; CVD; Inoperable stage I NSCLC; SBRT

Indexed keywords

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RELAPSE; CANCER STAGING; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBROSIS; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; STEREOTACTIC PROCEDURE; TREATMENT FAILURE; WHOLE BODY RADIATION;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; DOSE FRACTIONATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RADIOSURGERY; RADIOTHERAPY DOSAGE; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 52049099579     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.07.019     Document Type: Article

References (32)

1. Nagata Y., Takayama K., Matsuo Y., Norihisa Y., Mizowaki T., Sakamoto T., et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 63 (2005) 1427-1431
2. Onishi H. Stereotactic radiotherapy for body tumors (mainly lung). Nippon Hoshasen Gijutsu Gakkai Zasshi 62 (2006) 661-669
3. Onishi H., Shirato H., Nagata Y., Hiraoka M., Fujino M., Gomi K., et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2 (2007) S94-S100
4. Zimmermann F.B., Geinitz H., Schill S., Thamm R., Nieder C., Schratzenstaller U., et al. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol 45 (2006) 796-801
5. Timmerman R.D., Park C., and Kavanagh B.D. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol 2 (2007) S101-S112
6. Scorsetti M., Navarria P., Facoetti A., Lattuada P., Urso G., Mirandola A., et al. Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-stage lung cancer. Anticancer Res 27 (2007) 3615-3619
7. Nyman J., Johansson K.A., and Hulten U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer-mature results for medically inoperable patients. Lung Cancer 51 (2006) 97-103
8. McGarry R.C., Papiez L., Williams M., Whitford T., and Timmerman R.D. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 63 (2005) 1010-1015
9. http://www.roc.se/lungca.asp: Svenska lungcancer registret.
10. Ekberg-Aronsson M., Pehrsson K., Nilsson J.A., Nilsson P.M., and Lofdahl C.G. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 6 (2005) 98
11. http://ctep.cancer.gov.
12. www.rtog.org/members/toxicity/late.html.
13. Lax I., Blomgren H., Naslund I., and Svanstrom R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 33 (1994) 677-683
14. Baumann P., Nyman J., Lax I., Friesland S., Hoyer M., Rehn Ericsson S., et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 45 (2006) 787-795
15. Lax I., Panettieri V., Wennberg B., Amor Duch M., Naslund I., Baumann P., et al. Dose distributions in SBRT of lung tumors: comparison between two different treatment planning algorithms and Monte-Carlo simulation including breathing motions. Acta Oncol 45 (2006) 978-988
16. Panettieri V., Wennberg B., Gagliardi G., Duch M.A., Ginjaume M., and Lax I. SBRT of lung tumours: Monte Carlo simulation with PENELOPE of dose distributions including respiratory motion and comparison with different treatment planning systems. Phys Med Biol 52 (2007) 4265-4281
17. Djarv E., Nyman J., Baumann P., Ekberg L., Hoyer M., Lax I., et al. Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancer. Acta Oncol 45 (2006) 973-977
18. Bradley J. Radiographic response and clinical toxicity following SBRT for stage I lung cancer. J Thorac Oncol 2 (2007) S118-S124
19. Aoki T., Nagata Y., Negoro Y., Takayama K., Mizowaki T., Kokubo M., et al. Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. Radiology 230 (2004) 101-108
20. Kimura T., Matsuura K., Murakami Y., Hashimoto Y., Kenjo M., Kaneyasu Y., et al. CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers?. Int J Radiat Oncol Biol Phys 66 (2006) 483-491
21. Guckenberger M., Heilman K., Wulf J., Mueller G., Beckmann G., and Flentje M. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol 85 (2007) 435-442
22. Yamashita H., Nakagawa K., Nakamura N., Koyanagi H., Tago M., Igaki H., et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2 (2007) 21
23. Wulf J., Baier K., Mueller G., and Flentje M.P. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 77 (2005) 83-87
24. Timmerman R., Bastasch M., Saha D., Abdulrahman R., Hittson W., and Story M. Optimizing dose and fractionation for stereotactic body radiation therapy. Normal tissue and tumor control effects with large dose per fraction. Front Radiat Ther Oncol 40 (2007) 352-365
25. Timmerman R., McGarry R., Yiannoutsos C., Papiez L., Tudor K., DeLuca J., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24 (2006) 4833-4839
26. Kadono K., Homma T., Kamahara K., Nakayama M., Satoh H., Sekizawa K., et al. Effect of heavy-ion radiotherapy on pulmonary function in stage I non-small cell lung cancer patients. Chest 122 (2002) 1925-1932
27. Ohashi T., Takeda A., Shigematsu N., Kunieda E., Ishizaka A., Fukada J., et al. Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors. Int J Radiat Oncol Biol Phys 62 (2005) 1003-1008
28. Travis E.L., Liao Z.X., and Tucker S.L. Spatial heterogeneity of the volume effect for radiation pneumonitis in mouse lung. Int J Radiat Oncol Biol Phys 38 (1997) 1045-1054
29. Tucker S.L., Liao Z.X., and Travis E.L. Estimation of the spatial distribution of target cells for radiation pneumonitis in mouse lung. Int J Radiat Oncol Biol Phys 38 (1997) 1055-1066
30. Paludan M., Traberg Hansen A., Petersen J., Grau C., and Hoyer M. Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: is there a dose-volume dependency?. Acta Oncol 45 (2006) 818-822
31. Graham M.V., Purdy J.A., Emami B., Harms W., Bosch W., Lockett M.A., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45 (1999) 323-329
32. Henderson M., McGarry R., Yiannoutsos C., Fakiris A., Hoopes D., Williams M., et al. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2008)